(Total Views: 911)
Posted On: 11/20/2018 12:51:21 PM
Post# of 72446
JimmyBOY what experience is that? There were 29 biotech buyouts or mergers just in Nov/Dec/ 2017!!!!! Stop with your BULLSHIT!!!!
Did you know Glaxo and Smithkline MERGED on 12/31/2000?
Company Takeover candidate Deal Value $ Completed
3SBio (China) Therapure Biopharma (Canada) biomanufacturing business $290 million Dec 2017
Alembic
Pharmaceuticals
(India) Orit Laboratories (US) Undisclosed Nov 2017
Altimmune (US) PharmAthene (US) Undisclosed May 2017
Alvogen (US) Omega Bittner (Russia), from Perrigo (US) Undisclosed Oct 2017
Amneal (US) Impax Laboratories (US) Undisclosed all-stock merger Dec 2017
Arcturus Therapeutics (US) Alcobra (Israel) Reverse merger valued at $46.7 million Nov 2017
Astellas Pharma (Japan) Ogeda (Belgium) $856 million Nov 2017
Astellas Pharma (Japan) Mitobridge (US) $450 million of which $225 million upfront Dec 2017
Aurora Cannabis (Canada) Peloton Pharmaceuticals (Canada) $7 million Apr 2017
Bain Capital and Cinven consortium Stada Arzneimittel $4.36 billion Deal resurrected after being dropped on lack of shareholder support late June 2017; closed in Sept 2017
BioLineRx (Israel) Agalimmune (UK) $6 million 50:50 cash and shares deal Mar 2017
Biotoscana, Grupo (Uruguay) Laboratorio DOSA (Argentina) $30 million Nov 2017
Bioverativ (US) True North Therapeutics (US) $825 million of which $400 million upfront June 2017
Bristol-Myers Squibb (US) IFM Therapeutics (US) $300 million upfront and up to $2 billion in milestones Sept 2017
Carlyle Group and Pacific Equity Partners (US) iNova unit of Valeant Pharmaceuticals (Canada) $930 million Sept 2017
Carlyle and GCTR (US) Albany Molecular Research (US) $922 million Aug 2017
Catalent (US) Cook Pharmica (US) $950 million Oct 2017
Celgene (US) Delinia (US) $300 million upfront with $475 million contingent May 2017
Cell Medica (UK) Catapult Therapy TCR Undisclosed June 2017
Chengdu Kanghong Pharma (China) IOPtima from BioLight (Israel) $23-27 million to complete in stages Nov 2017
Clinigen Group (UK) Quantum Pharma (UK) $190 million Nov 2017
Collidion (US) Plex Pharmaceuticals (US) Undisclosed sum for 80% Aug 2017
CSL Limited (Australia) Wuhan Zhong Yuan Rui De Biological Products Wuhan Zhong Yuan Rui De Biological Products Aug 2017
CSL Limited (Australia) Calimmune (US) $91 million upfront and $325 million contingent Sept 2017
Creat Group Corp (China) Biotest (Germany) $1.3 billion Offer withdrawn in Nov 2017
CVS Health (US) Aetna (US) $69 billion Exp. 2nd half-2018
Ethypharm (France) Martindale Pharma (UK) Merger, value undisclosed Jan 2017
Evotec (Germany) Aptuit (USA) $300 million Aug 2017
Fosun Pharmaceutical (China) Tridem (France) $73 million Nov 2017
Fresenius Kabi (Germany) Akorn (US) $4.3 billion Exp. early 2018
Fresenius Kabi (Germany) Biosimilars business of Merck KGaA (Germany) $730 million Sept 2017
FujiFilm (Japan) EdiGene (Japan) $4 million for 11.7% equity stake Dec 2017
GenScript Biotech (Hong Kong) CustomArray (US) Undiclosed Exp.early 2018
Gilead Sciences (US) Kite Pharma (US) $11.9 billion Oct 2017
Gilead Sciences (US) Cell Design Labs (US) $175 million upfront, $322 million contingent Dec 2017
GL Capital-led consortium of Chinese investors SciClone Pharmaceutical (US) $605 million Oct 2017
Grifols (Spain) GigaGen (US) $35 million for 43.96% equity stake July 2017
Gurnet Point Capital (US) Innocoll Holdings (Ireland) $209 million July 2017
Haitong International Zhongua Finance (Hong Kong) Obagi Medical Products from Valeant Pharmaceutical (Canada) $190 million Nov 2017
Heat Biologics (US) Pelican Therapeutics (US) $1.5 million Apr 2017
Horizon Pharma (Ireland) River Vision Development (US) $145 million plus contingent payments May 2017
ImmunoPrecise (Canada) Preclinics (Germany) $2.7 million plus $895,500 contingent Early 2018
Kitov Pharmaceuticals (Israel) TyrNovo (Israel) $3.8 million ($2 million cash) for initial 56% equity stake. Acquired additional 27% stake for $7 million in shares Oct 2017
Eli Lilly (US) CoLucid (US) $960 million Mar 2017
Intrexon (US) GenVec (US) Undisclosed, all share transaction June 2017
Invent Farma/neuraxpharm (Spain) FB Health (Italy) Undisclosed June 2017
Johnson & Johnson (US) Actelion (Switzerland) $30 billion with spin-out of early-stage R&D Jan 2017
JSR Life Sciences (Japan) Selexis (Switzerland) Undisclosed June 2017
JSR Life Sciences (Japan) Crown Bioscience International (US) $400 million Ann. Dec 2017
Ligand Pharmaceuticals (US) Crystal Biosciences (US) $25 million plus $10.5 million contingent Dec 2017
Lupin (India) Symbiomix Therapeutics (US) $150 million, $50 million upfront Oct 2017
Mallinckrodt (US) InfaCare (US) $80 million upfront and $345 million contingent Dec 2017
Mallinckrodt (US) Ocera Therapeutics (US) $42 million plus up to $75 million contingent Dec 2017
Mallinckrodt (US) Sucampo Pharmaceuticals (US) $1.2 billion Exp. 1st-qtr 2018
Medicure (Canada) Apicore (US) $24.5 million for additional 32% equity stake July 2017
Melinta Therapeutics (US) Infectious disease business of The Medicines Company $270 million upfront plus $215 million contingent Exp. 1st-qtr 2018
Mercachem (Netherlands) Syncom (Netherlands) Undisclosed, merger of CROs Aug 2017
Merck & Co (US) Rigonetic (Germany) $600 million of which $137 million upfront Nov 2017
Millendo Therapeutics (US) Alizé Pharma SAS (France) Undisclosed stock transaction Dec 2017
Mitsubishi Tanabe Pharma (Japan) NeuroDerm (Israel) $1.1 billion Oct 2017
Molecular Templates (US) Threshold Pharmaceuticals (US) All-stock merger Aug 2017
Norgine (Netherlands) Merus Labs International (Canada) $342 million July 2017
Onzima Ventures (UK) N4 Pharma (UK) 51% not already owned; share deal Apr 2017
Otsuka Pharmaceutical (Japan) Neurovance (US) $100 million upfront and $150 million contingent June 2017
Pamplona Capital Management Parexel (US) $5 billion Sept 2017
PDL Biopharma (US) Neos Therapeutics (US) Unsolicited takeover offer of ~$287.8 million Rejected by Neos in Oct 2017
Quotient Sciences (UK) Pharmaterials (UK) Undisclosed Nov 2017
Regenxbio (US) Dimension Therapeutics (US) $86 million (later counter bid by Ultragenyx) Not consummated
Repligen (US) Spectrum Inc (US) $359 million, of which $120 million in cash Aug 2017
Roche (Switzerland) ForSight Vision4 (US) Undisclosed Jan 2017
Roche (Switzerland) Ignyta (US) $1.7 billion Exp. 1st-half 2018
Roquette (France) Itacel (Brazil) Undisclosed Sept 2017
Rostec (Russia) Marathon Group (Russia) Undisclosed merger Dec 2017
Sapphire (HK) Holdings (China) Hisun-Pfizer Pharma (US) Undisclosed, 49% stake from Pfizer Nov 2017
Sawai Pharmaceuticals (Japan) Generics business of Upsher-Smith (US) $1.05 billion June 2017
Sanofi (France) Protein Sciences (US) $650 million plus $100 million contingent Aug 2017
Savara (US) Mast Therapeutics (US) Undisclosed with a transaction value of around $150 million Exp. 2nd-qtr 2017
Sanpower (China) Dendreon (US) from Valeant Pharma (US) $819.9million June 2017
Sellas Life Sciences (Swiss/Greek) Galena Biopharma (US) Undisclosed, all stock merger Dec 2017
Sevion Therapeutics (US) Eloxx Pharmaceuticals (Israel) Undisclosed share deal Nov 2017
Sihuan Pharma (China) Ambest Pharmaceutical (China) $160 million Ann. Mar 2017
Silence Therapeutics (UK) Arrowhead Pharmaceuticals (US) $9.6 million for 8.4% equity stake Jan 2017
SK Capital (US) Perrigo API, the ingredients unit of Perrigo (Ireland) $110 million Nov 2017
Did you know Glaxo and Smithkline MERGED on 12/31/2000?
Company Takeover candidate Deal Value $ Completed
3SBio (China) Therapure Biopharma (Canada) biomanufacturing business $290 million Dec 2017
Alembic
Pharmaceuticals
(India) Orit Laboratories (US) Undisclosed Nov 2017
Altimmune (US) PharmAthene (US) Undisclosed May 2017
Alvogen (US) Omega Bittner (Russia), from Perrigo (US) Undisclosed Oct 2017
Amneal (US) Impax Laboratories (US) Undisclosed all-stock merger Dec 2017
Arcturus Therapeutics (US) Alcobra (Israel) Reverse merger valued at $46.7 million Nov 2017
Astellas Pharma (Japan) Ogeda (Belgium) $856 million Nov 2017
Astellas Pharma (Japan) Mitobridge (US) $450 million of which $225 million upfront Dec 2017
Aurora Cannabis (Canada) Peloton Pharmaceuticals (Canada) $7 million Apr 2017
Bain Capital and Cinven consortium Stada Arzneimittel $4.36 billion Deal resurrected after being dropped on lack of shareholder support late June 2017; closed in Sept 2017
BioLineRx (Israel) Agalimmune (UK) $6 million 50:50 cash and shares deal Mar 2017
Biotoscana, Grupo (Uruguay) Laboratorio DOSA (Argentina) $30 million Nov 2017
Bioverativ (US) True North Therapeutics (US) $825 million of which $400 million upfront June 2017
Bristol-Myers Squibb (US) IFM Therapeutics (US) $300 million upfront and up to $2 billion in milestones Sept 2017
Carlyle Group and Pacific Equity Partners (US) iNova unit of Valeant Pharmaceuticals (Canada) $930 million Sept 2017
Carlyle and GCTR (US) Albany Molecular Research (US) $922 million Aug 2017
Catalent (US) Cook Pharmica (US) $950 million Oct 2017
Celgene (US) Delinia (US) $300 million upfront with $475 million contingent May 2017
Cell Medica (UK) Catapult Therapy TCR Undisclosed June 2017
Chengdu Kanghong Pharma (China) IOPtima from BioLight (Israel) $23-27 million to complete in stages Nov 2017
Clinigen Group (UK) Quantum Pharma (UK) $190 million Nov 2017
Collidion (US) Plex Pharmaceuticals (US) Undisclosed sum for 80% Aug 2017
CSL Limited (Australia) Wuhan Zhong Yuan Rui De Biological Products Wuhan Zhong Yuan Rui De Biological Products Aug 2017
CSL Limited (Australia) Calimmune (US) $91 million upfront and $325 million contingent Sept 2017
Creat Group Corp (China) Biotest (Germany) $1.3 billion Offer withdrawn in Nov 2017
CVS Health (US) Aetna (US) $69 billion Exp. 2nd half-2018
Ethypharm (France) Martindale Pharma (UK) Merger, value undisclosed Jan 2017
Evotec (Germany) Aptuit (USA) $300 million Aug 2017
Fosun Pharmaceutical (China) Tridem (France) $73 million Nov 2017
Fresenius Kabi (Germany) Akorn (US) $4.3 billion Exp. early 2018
Fresenius Kabi (Germany) Biosimilars business of Merck KGaA (Germany) $730 million Sept 2017
FujiFilm (Japan) EdiGene (Japan) $4 million for 11.7% equity stake Dec 2017
GenScript Biotech (Hong Kong) CustomArray (US) Undiclosed Exp.early 2018
Gilead Sciences (US) Kite Pharma (US) $11.9 billion Oct 2017
Gilead Sciences (US) Cell Design Labs (US) $175 million upfront, $322 million contingent Dec 2017
GL Capital-led consortium of Chinese investors SciClone Pharmaceutical (US) $605 million Oct 2017
Grifols (Spain) GigaGen (US) $35 million for 43.96% equity stake July 2017
Gurnet Point Capital (US) Innocoll Holdings (Ireland) $209 million July 2017
Haitong International Zhongua Finance (Hong Kong) Obagi Medical Products from Valeant Pharmaceutical (Canada) $190 million Nov 2017
Heat Biologics (US) Pelican Therapeutics (US) $1.5 million Apr 2017
Horizon Pharma (Ireland) River Vision Development (US) $145 million plus contingent payments May 2017
ImmunoPrecise (Canada) Preclinics (Germany) $2.7 million plus $895,500 contingent Early 2018
Kitov Pharmaceuticals (Israel) TyrNovo (Israel) $3.8 million ($2 million cash) for initial 56% equity stake. Acquired additional 27% stake for $7 million in shares Oct 2017
Eli Lilly (US) CoLucid (US) $960 million Mar 2017
Intrexon (US) GenVec (US) Undisclosed, all share transaction June 2017
Invent Farma/neuraxpharm (Spain) FB Health (Italy) Undisclosed June 2017
Johnson & Johnson (US) Actelion (Switzerland) $30 billion with spin-out of early-stage R&D Jan 2017
JSR Life Sciences (Japan) Selexis (Switzerland) Undisclosed June 2017
JSR Life Sciences (Japan) Crown Bioscience International (US) $400 million Ann. Dec 2017
Ligand Pharmaceuticals (US) Crystal Biosciences (US) $25 million plus $10.5 million contingent Dec 2017
Lupin (India) Symbiomix Therapeutics (US) $150 million, $50 million upfront Oct 2017
Mallinckrodt (US) InfaCare (US) $80 million upfront and $345 million contingent Dec 2017
Mallinckrodt (US) Ocera Therapeutics (US) $42 million plus up to $75 million contingent Dec 2017
Mallinckrodt (US) Sucampo Pharmaceuticals (US) $1.2 billion Exp. 1st-qtr 2018
Medicure (Canada) Apicore (US) $24.5 million for additional 32% equity stake July 2017
Melinta Therapeutics (US) Infectious disease business of The Medicines Company $270 million upfront plus $215 million contingent Exp. 1st-qtr 2018
Mercachem (Netherlands) Syncom (Netherlands) Undisclosed, merger of CROs Aug 2017
Merck & Co (US) Rigonetic (Germany) $600 million of which $137 million upfront Nov 2017
Millendo Therapeutics (US) Alizé Pharma SAS (France) Undisclosed stock transaction Dec 2017
Mitsubishi Tanabe Pharma (Japan) NeuroDerm (Israel) $1.1 billion Oct 2017
Molecular Templates (US) Threshold Pharmaceuticals (US) All-stock merger Aug 2017
Norgine (Netherlands) Merus Labs International (Canada) $342 million July 2017
Onzima Ventures (UK) N4 Pharma (UK) 51% not already owned; share deal Apr 2017
Otsuka Pharmaceutical (Japan) Neurovance (US) $100 million upfront and $150 million contingent June 2017
Pamplona Capital Management Parexel (US) $5 billion Sept 2017
PDL Biopharma (US) Neos Therapeutics (US) Unsolicited takeover offer of ~$287.8 million Rejected by Neos in Oct 2017
Quotient Sciences (UK) Pharmaterials (UK) Undisclosed Nov 2017
Regenxbio (US) Dimension Therapeutics (US) $86 million (later counter bid by Ultragenyx) Not consummated
Repligen (US) Spectrum Inc (US) $359 million, of which $120 million in cash Aug 2017
Roche (Switzerland) ForSight Vision4 (US) Undisclosed Jan 2017
Roche (Switzerland) Ignyta (US) $1.7 billion Exp. 1st-half 2018
Roquette (France) Itacel (Brazil) Undisclosed Sept 2017
Rostec (Russia) Marathon Group (Russia) Undisclosed merger Dec 2017
Sapphire (HK) Holdings (China) Hisun-Pfizer Pharma (US) Undisclosed, 49% stake from Pfizer Nov 2017
Sawai Pharmaceuticals (Japan) Generics business of Upsher-Smith (US) $1.05 billion June 2017
Sanofi (France) Protein Sciences (US) $650 million plus $100 million contingent Aug 2017
Savara (US) Mast Therapeutics (US) Undisclosed with a transaction value of around $150 million Exp. 2nd-qtr 2017
Sanpower (China) Dendreon (US) from Valeant Pharma (US) $819.9million June 2017
Sellas Life Sciences (Swiss/Greek) Galena Biopharma (US) Undisclosed, all stock merger Dec 2017
Sevion Therapeutics (US) Eloxx Pharmaceuticals (Israel) Undisclosed share deal Nov 2017
Sihuan Pharma (China) Ambest Pharmaceutical (China) $160 million Ann. Mar 2017
Silence Therapeutics (UK) Arrowhead Pharmaceuticals (US) $9.6 million for 8.4% equity stake Jan 2017
SK Capital (US) Perrigo API, the ingredients unit of Perrigo (Ireland) $110 million Nov 2017
(16)
(0)
